ZyStor, based in Milwaukee Wisconsin, is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs). Its lead product is for Pompe patients.
Co-Investors: Mason-Wells, Prolog Ventures, Venture Investors, State of Wisconsin Investment Board, Hexagon Investments, Stonehenge Capital
Co-Investors: Mason-Wells, Prolog Ventures, Venture Investors, State of Wisconsin Investment Board, Hexagon Investments, Stonehenge Capital
Employees: 1001-5000